How many drugs treat Follicular lymphoma?

Drug Landscape tracks 10 marketed treatments for Follicular lymphoma (deduplicated by molecule). 0 Phase 3 candidates and 0 Phase 2 candidates are in the pipeline.

How do I subscribe to ongoing alerts?

Subscribe to /feed/disease/follicular-lymphoma.xml in Feedly / Inoreader. Every regulatory action, PDUFA date, or trial completion in this treatment area lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

Follicular lymphoma — Treatment Landscape & Competitive Intelligence

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Follicular lymphoma (disease) competitive landscape: 10 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

10 marketed 0 Phase 3 0 Phase 2 Live · 30-min refresh

Marketed treatment landscape

Approved drugs treating Follicular lymphoma, deduplicated by molecule. See the full disease page for line-of-therapy detail.

Drug	Generic	Sponsor	Class	Target	First approval
Tazverik	TAZEMETOSTAT	Epizyme Inc	Methyltransferase Inhibitor	Polycomb protein EED	2020-01-01
Aliqopa	COPANLISIB	Bayer	Kinase Inhibitor	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform	2017-01-01
Revlimid	lenalidomide	Bristol-Myers Squibb	Thalidomide analogue	Cereblon (component of cullin ring E3 ubiquitin ligase enzyme complex)	2005-01-01
Mabthera	Rituximab-Pvvr	Roche	Monoclonal antibody	CD20 antigen on pre-B and mature B-lymphocytes	1997-01-01
Mabthera	rituximab	Roche	CD20-directed Cytolytic Antibody [EPC]	B-lymphocyte antigen CD20	1997-01-01
Mabthera	rituxan	Roche	CD20-directed Cytolytic Antibody	B-lymphocyte antigen CD20	1997-01-01
Intron A	INTERFERON ALFA-2B	Merck & Co.	Interferon alpha		1986-01-01
Lenali	Lenali	Singapore General Hospital		Bromodomain-containing protein 4, Protein cereblon, Tumor necrosis factor
Revlimid	Revlimid	M.D. Anderson Cancer Center		Bromodomain-containing protein 4, Protein cereblon, Tumor necrosis factor
Tazverik	Tazverik	Edwin Posadas, MD		Polycomb protein EED, Histone-lysine N-methyltransferase EZH1, Histone-lysine N-methyltransferase EZH2

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this treatment set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

Roche · 3 drugs in Follicular lymphoma
Epizyme Inc · 2 drugs in Follicular lymphoma
Edwin Posadas, MD · 1 drug in Follicular lymphoma
M.D. Anderson Cancer Center · 1 drug in Follicular lymphoma
Merck & Co. · 1 drug in Follicular lymphoma
Bayer · 1 drug in Follicular lymphoma
Singapore General Hospital · 1 drug in Follicular lymphoma
Bristol-Myers Squibb · 1 drug in Follicular lymphoma

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in Follicular lymphoma:

Cite this brief

Drug Landscape (2026). Follicular lymphoma — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/follicular-lymphoma. Accessed 2026-06-10.

Follicular lymphoma full disease profile — treatment pathway, diagnostics, guidelines
Browse all CI briefs
Build a custom feed

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing